World Asset Management Inc Sells 1,116 Shares of Merck & Co., Inc. (NYSE:MRK)

World Asset Management Inc lessened its position in shares of Merck & Co., Inc. (NYSE:MRK) by 1.6% during the second quarter, HoldingsChannel.com reports. The fund owned 70,378 shares of the company’s stock after selling 1,116 shares during the period. World Asset Management Inc’s holdings in Merck & Co., Inc. were worth $5,473,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of MRK. Cowen Prime Advisors LLC bought a new stake in Merck & Co., Inc. during the 2nd quarter worth approximately $31,000. AlphaMark Advisors LLC bought a new position in shares of Merck & Co., Inc. in the 2nd quarter worth $39,000. Lake Point Wealth Management bought a new position in shares of Merck & Co., Inc. during the 2nd quarter valued at $40,000. ShoreHaven Wealth Partners LLC grew its holdings in shares of Merck & Co., Inc. by 55.5% during the 1st quarter. ShoreHaven Wealth Partners LLC now owns 619 shares of the company’s stock valued at $48,000 after purchasing an additional 221 shares during the last quarter. Finally, Solstein Capital LLC bought a new position in shares of Merck & Co., Inc. during the 1st quarter valued at $54,000. 71.83% of the stock is currently owned by institutional investors and hedge funds.

NYSE:MRK traded up $0.52 during trading hours on Wednesday, hitting $72.63. 265,384 shares of the stock traded hands, compared to its average volume of 11,229,302. The company has a quick ratio of 1.06, a current ratio of 1.31 and a debt-to-equity ratio of 0.72. Merck & Co., Inc. has a 1 year low of $71.71 and a 1 year high of $86.30. The company has a market cap of $183.85 billion, a price-to-earnings ratio of 32.93, a price-to-earnings-growth ratio of 2.16 and a beta of 0.41. The stock has a 50 day moving average price of $76.68 and a 200 day moving average price of $76.59.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Wednesday, July 28th. The company reported $1.31 earnings per share for the quarter, meeting the consensus estimate of $1.31. Merck & Co., Inc. had a net margin of 11.48% and a return on equity of 50.93%. The business had revenue of $11.40 billion for the quarter, compared to the consensus estimate of $11.21 billion. During the same quarter in the previous year, the firm earned $1.37 earnings per share. Equities analysts forecast that Merck & Co., Inc. will post 5.51 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 7th. Shareholders of record on Wednesday, September 15th will be issued a dividend of $0.65 per share. This represents a $2.60 annualized dividend and a yield of 3.58%. The ex-dividend date of this dividend is Tuesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is currently 43.77%.

Several equities analysts recently commented on the stock. Zacks Investment Research raised shares of Merck & Co., Inc. from a “sell” rating to a “hold” rating and set a $82.00 target price on the stock in a report on Tuesday, August 24th. Truist Securities initiated coverage on shares of Merck & Co., Inc. in a research note on Tuesday, July 27th. They set a “buy” rating and a $76.79 price objective for the company. JPMorgan Chase & Co. reduced their price objective on shares of Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating for the company in a research note on Wednesday, June 9th. Truist started coverage on shares of Merck & Co., Inc. in a research note on Tuesday, July 27th. They issued a “buy” rating and a $92.00 price target for the company. Finally, Morgan Stanley lowered shares of Merck & Co., Inc. from an “overweight” rating to an “equal weight” rating and reduced their price target for the stock from $90.00 to $85.00 in a research note on Tuesday, September 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $91.09.

Merck & Co., Inc. Company Profile

Merck & Co, Inc engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Recommended Story: Technical Analysis of Stocks and What It Means

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.